Atea Pharmaceuticals (AVIR) Change in Accured Expenses (2019 - 2026)

Atea Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at -$2.7 million for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 880.69% year-over-year to -$2.7 million; the TTM figure through Mar 2026 stood at $9.6 million (up 282.45% YoY), while the FY2025 annual figure was $12.7 million, up 194.26% from the prior year.
• Change in Accured Expenses was -$2.7 million for Q1 2026 at Atea Pharmaceuticals, down from $9.7 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $9.8 million in Q4 2023 to a low of -$28.0 million in Q1 2022.
• Historically, Change in Accured Expenses has averaged -$1.7 million across 5 years, with a median of $347000.0 in 2025.
• The sharpest annual moves came in 2023 and 2026: Change in Accured Expenses jumped 556.59% in 2023, then plunged 880.69% in 2026.
• A 5-year view of Change in Accured Expenses shows it stood at $1.5 million in 2022, then surged by 556.59% to $9.8 million in 2023, then plunged by 152.42% to -$5.1 million in 2024, then soared by 290.21% to $9.7 million in 2025, then sank by 127.84% to -$2.7 million in 2026.
• The last three Change in Accured Expenses figures came in at -$2.7 million (Q1 2026), $9.7 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.